Brief Report - (2025) Volume 12, Issue 6
Received: 01-Dec-2025, Manuscript No. jpd-26-183946;
Editor assigned: 03-Dec-2025, Pre QC No. P-183946;
Reviewed: 17-Dec-2025, QC No. Q-183946;
Revised: 22-Dec-2025, Manuscript No. R-183946;
Published:
29-Dec-2025
, DOI: 10.37421/2684-4281.2025.12.550
Citation: Boussaid, Fatima Z.. ”Biologic Dermatology: Adverse Effects and Management Strategies.” J Dermatol Dis 12 (2025):550.
Copyright: © 2025 Boussaid Z. Fatima This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Biologic therapies have dramatically transformed the management of numerous dermatologic conditions, offering unprecedented efficacy in treating various inflammatory and autoimmune skin diseases. However, their immunomodulatory mechanisms, while therapeutic, are also associated with a distinct spectrum of cutaneous adverse events. Understanding these potential side effects is paramount for clinicians to ensure optimal patient outcomes and safety. This review aims to elucidate the multifaceted dermatologic reactions that can arise from the use of these advanced therapeutic agents [1].
One significant area of concern with biologic therapy is the increased susceptibility to infections. Patients receiving these treatments often have a modulated immune system, making them more vulnerable to a range of microbial pathogens. This systematic review and meta-analysis specifically addresses the incidence and characteristics of infections in patients with psoriasis and psoriatic arthritis treated with biologics, providing crucial data on common pathogens and risk factors [2].
Beyond infectious complications, hypersensitivity reactions represent another critical class of adverse events associated with biologic treatments. These reactions can range in severity from mild cutaneous manifestations to life-threatening anaphylaxis, necessitating careful monitoring and prompt intervention. This article delves into the immunological underpinnings of these reactions and offers practical guidelines for their diagnosis and management [3].
A particularly intriguing and clinically challenging phenomenon observed with biologic therapy is the occurrence of paradoxical reactions. In these instances, patients may develop symptoms of the disease being treated, or even new dermatological conditions, despite receiving the intended therapeutic agent. This review comprehensively examines the current understanding of paradoxical reactions, their clinical presentation, and potential management strategies [4].
Specific biologic agents have also been associated with distinct dermatologic adverse events, particularly in the context of their approved indications. This study focuses on the skin adverse events observed with dupilumab in patients with atopic dermatitis, offering insights into common side effects such as injection site reactions and exacerbations of pre-existing conditions, as well as rarer but significant reactions [5].
The management of skin infections in individuals undergoing biologic therapy presents a unique clinical challenge, requiring a nuanced approach that considers both the patient's immune status and the specific biologic agent being used. This review provides a practical framework for identifying, classifying, and effectively treating various types of skin infections that may occur in this immunocompromised patient population [6].
Furthermore, there is a recognized potential for biologic therapies to induce or exacerbate autoimmune conditions. This class effect, observed with certain agents, necessitates careful monitoring and diagnostic acumen. This article explores the types of autoimmune events associated with biologics, their temporal relationship to treatment initiation, and strategies for their diagnosis and management [7].
As the landscape of biologic therapies for dermatological diseases continues to expand with the development of newer agents, so too does our understanding of their associated dermatologic adverse effects. This review offers an updated perspective on the cutaneous reactions linked to the latest generation of biologic agents, highlighting challenges in attribution and management, and emphasizing the need for ongoing surveillance [8].
Among the spectrum of potential autoimmune phenomena, drug-induced lupus erythematosus (DILE) is a recognized, albeit infrequent, adverse effect of several systemic medications, including certain biologics. This article provides a detailed overview of the clinical features, diagnostic criteria, and management of DILE, stressing the importance of early recognition and discontinuation of the causative agent [9].
Finally, for biologics administered via subcutaneous injection, injection site reactions are a common concern. This prospective study evaluates the incidence and management of these reactions, identifying typical manifestations and exploring strategies to mitigate patient discomfort and improve therapeutic adherence. The findings underscore the importance of patient education and proactive management of these localized events [10].
The advent of biologic therapies has marked a significant paradigm shift in dermatology, offering targeted treatments for a wide array of inflammatory and autoimmune skin conditions. While their efficacy is undeniable, these powerful agents are also associated with a predictable, yet varied, array of cutaneous adverse events that clinicians must be prepared to manage. Understanding the full spectrum of these reactions is critical for optimizing patient care and minimizing potential harm. This review meticulously details the common and less frequent dermatologic reactions to biologics, encompassing a broad range of potential complications, from infections and hypersensitivity to paradoxical reactions and exacerbations of underlying conditions [1].
A substantial concern when utilizing immunosuppressive or immunomodulatory agents like biologics is the heightened risk of infections. Patients on these therapies often experience alterations in their immune responses, rendering them more susceptible to a variety of bacterial, viral, and fungal pathogens. This systematic review and meta-analysis provides a thorough investigation into the incidence and specific characteristics of infections that arise in patients with psoriasis and psoriatic arthritis undergoing biologic treatment, offering valuable insights into prevalent pathogens and identifying key risk factors that predispose individuals to these complications [2].
Hypersensitivity reactions are another prominent category of adverse events linked to biologic agents, capable of manifesting with a diverse range of clinical presentations, from mild dermatological manifestations to severe, life-threatening anaphylactic episodes. The immunological mechanisms underlying these reactions are complex, and this article provides a comprehensive examination of these pathways, alongside practical, evidence-based guidelines for their accurate diagnosis and effective management, including specialized protocols for desensitization when indicated [3].
Paradoxical reactions, a phenomenon where patients develop new or worsening symptoms of the condition being treated, or even entirely new dermatoses, while on biologic therapy, represent a significant and often perplexing clinical challenge. This paper offers a detailed review of the current understanding of paradoxical reactions, their characteristic clinical manifestations, and discusses various management strategies that may be employed, including adjustments to the biologic regimen or discontinuation of the agent [4].
When considering specific biologic agents, it is important to acknowledge that some may be associated with particular dermatologic adverse events. This study meticulously examines the spectrum of skin adverse events observed in patients treated with dupilumab for atopic dermatitis. It provides an overview of frequently encountered side effects, such as injection site reactions and the exacerbation of existing skin conditions, in addition to discussing rarer but clinically significant reactions, emphasizing the importance of tailored patient education and vigilant monitoring [5].
The presence of skin infections in patients receiving biologic therapy necessitates a carefully considered approach to management. The specific biologic agent and the patient's overall immune status are crucial factors in determining the most appropriate treatment strategy. This review presents a practical and systematic approach to the identification, classification, and effective treatment of various skin infections, including bacterial, viral, and fungal infections, within this vulnerable patient population [6].
Certain biologic agents have also been associated with the induction or exacerbation of autoimmune conditions. This potential class effect warrants careful consideration, and this article systematically explores the various types of autoimmune events that have been observed in patients treated with biologics, examining their temporal relationship to the initiation of therapy and outlining strategies for their accurate diagnosis and effective management [7].
With the continuous development and introduction of novel biologic agents for dermatological diseases, our understanding of their associated cutaneous adverse events is also evolving. This review provides an updated and comprehensive overview of the dermatologic adverse effects linked to the newest generation of biologic agents. It addresses the inherent challenges in attributing specific reactions to these agents and discusses contemporary management strategies, underscoring the critical need for ongoing surveillance and research to ensure patient safety [8].
Drug-induced lupus erythematosus (DILE) is a recognized, though uncommon, adverse reaction associated with several systemic medications, including some biologic therapies. This article meticulously details the clinical features characteristic of DILE, outlines the diagnostic criteria used for its confirmation, and discusses various treatment approaches, with a particular emphasis on the importance of prompt recognition and the discontinuation of the offending agent to facilitate recovery [9].
For patients receiving subcutaneous biologic therapies for inflammatory skin diseases, injection site reactions are a common and potentially bothersome adverse event. This prospective study was designed to evaluate the incidence and effective management of these reactions. It identifies the most common types of reactions encountered, assesses patient-reported outcomes, and explores various strategies aimed at alleviating discomfort and improving patient adherence to ongoing therapy [10].
Biologic therapies have revolutionized dermatology but are associated with various skin adverse effects. These include increased risk of infections, hypersensitivity reactions, and paradoxical reactions where symptoms worsen or new conditions appear. Specific biologics like dupilumab have known side effects, such as injection site reactions and exacerbations. Autoimmune phenomena and drug-induced lupus erythematosus can also occur. Effective management involves early detection, risk factor assessment, tailored patient education, and appropriate treatment strategies. Newer agents continue to emerge, necessitating ongoing surveillance and research to ensure patient safety.
None
None
Journal of Dermatology and Dermatologic Diseases received 4 citations as per Google Scholar report
